MedTrace Logo

Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy

NCT01884168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-02-07

No results posted yet for this study

Summary

To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immunotherapy.

Conditions

  • Malignant Tumor

Interventions

BIOLOGICAL

Dc-CIK immunotherapy

The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Jun Ren, MD, PhD · Capital Medical University Cancer Center /Beijing Shijitan Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2022-12-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884168 on ClinicalTrials.gov